EASTON BIOPHARMACEUTICALS: Ailamod Tablets have obtained a drug registration certificate
EASTON BIOPHARMACEUTICALS announced that its wholly-owned subsidiary Chengdu ShuoDe Pharmaceutical has obtained the "Drug Registration Certificate" issued by the National Medical Products Administration. The drug is Elamomab tablets, indicated for active rheumatoid arthritis, and is classified as a Category B drug in the National Basic Medical Insurance Drug List for 2024
According to the Zhitong Finance APP, EASTON BIOPHARMACEUTICALS (688513.SH) announced that it has obtained the drug registration certificate for Aitamod tablets. The company's wholly-owned subsidiary, Chengdu ShuoDe Pharmaceutical Co., Ltd. (hereinafter referred to as "ShuoDe Pharmaceutical"), recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), concerning the drug: "Aitamod tablets."
The active ingredient of Aitamod tablets is Aitamod, and the indication is active rheumatoid arthritis. Aitamod tablets are classified as Category B in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024)."
